Smith & Nephew PLC (MEX:SN1 N) Stock Price, Trades & News

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.17
Equity-to-Asset	0.51
Debt-to-Equity	0.63
Debt-to-EBITDA	2.19
Interest Coverage	4.78
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	3.37	Distress Grey Safe
Beneish M-Score	-2.72	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	2.5
	3-Year EBITDA Growth Rate	16.8
	3-Year EPS without NRI Growth Rate	-4.8
	3-Year FCF Growth Rate	92
	3-Year Book Growth Rate	-2.1
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	11.93
	Future 3-5Y Total Revenue Growth Rate Estimate	5.87

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.57
	Quick Ratio	1.25
	Cash Ratio	0.35
	Days Inventory	439.32
	Days Sales Outstanding	73.37
	Days Payable	210.27

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Payout Ratio	0.54
	3-Year Dividend Growth Rate	-3.8
	3-Year Average Share Buyback Ratio	0.8
	Shareholder Yield %	8.85

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	67.99
	Operating Margin %	13.9
	Net Margin %	10.14
	EBITDA Margin %	24.86
	FCF Margin %	13.7
	OCF Margin %	20.66
	ROE %	11.41
	ROA %	5.83
	ROIC %	7.88
	3-Year ROIIC %	-4.16
	ROC (Joel Greenblatt) %	25.12
	ROCE %	10.49
	Years of Profitability over Past 10-Year	10
	Moat Score	7
	Tariff Resilience Score	6

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	21.21
	Forward PE Ratio	12.85
	PE Ratio without NRI	21.21
	Shiller PE Ratio	19.65
	Price-to-Owner-Earnings	13.2
	PEG Ratio	2.33
	PS Ratio	2.15
	PB Ratio	2.42
	Price-to-Tangible-Book	9.88
	Price-to-Free-Cash-Flow	15.47
	Price-to-Operating-Cash-Flow	10.25
	EV-to-EBIT	16.33
	EV-to-Forward-EBIT	17.82
	EV-to-EBITDA	10.21
	EV-to-Forward-EBITDA	10.63
	EV-to-Revenue	2.54
	EV-to-Forward-Revenue	2.49
	EV-to-FCF	18.32
	Price-to-GF-Value	0.95
	Price-to-Projected-FCF	1.42
	Price-to-Median-PS-Value	0.67
	Price-to-Peter-Lynch-Fair-Value	2.14
	Price-to-Graham-Number	3.05
	Earnings Yield (Greenblatt) %	6.12
	FCF Yield %	6.66
	Forward Rate of Return (Yacktman) %	12.61

Financials (Next Earnings Date:2026-08-26)

Annual Quarterly TTM

MEX:SN1 N's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Smith & Nephew PLC Executives

Details

GF Value™: MXN271.36

MEX:SN1 N

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with SN1 N. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil MXN)	114,199.88
	EPS (TTM) (MXN)	13.255
	Beta	-0.4859
	3-Year Sharpe Ratio	-0.28
	3-Year Sortino Ratio	-0.42
	Volatility %	1.91
	14-Day RSI	-
	14-Day ATR (MXN)	-
	20-Day SMA (MXN)	256.55
	12-1 Month Momentum %	-
	52-Week Range (MXN)	256.55 - 256.55
	Shares Outstanding (Mil)	845.04

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Smith & Nephew PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Smith & Nephew PLC Stock Events

Financials Calendars

Event	Date	Price (MXN)
Second quarter earnings conference call for 2026	2026-08-26	In 48 days
Second quarter earnings results for 2026	2026-08-26	In 48 days
General meeting for 2026	2026-05-06 11:00	256.55 (+0.00%)
Smith & Nephew PLC Smith+Nephew Q1 Trading Report	2026-05-06 07:30	256.55 (+0.00%)
USD 0.241000 Cash Dividend	2026-03-27	256.55 (+0.00%)
Annual report for 2025	2026-03-16	256.55 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-03-02 03:30	256.55 (+0.00%)
Fourth quarter earnings results for 2025	2026-03-02 02:00	256.55 (+0.00%)
New York Capital Markets Day	2025-12-11 09:00	256.55 (+0.00%)
London Capital Markets Day	2025-12-08 08:00	256.55 (+0.00%)

Show

Entries

Smith & Nephew PLC Frequently Asked Questions

What is Smith & Nephew PLC(MEX:SN1 N)'s stock price today?

The current price of MEX:SN1 N is MXN256.55. The 52 week high of MEX:SN1 N is MXN256.55 and 52 week low is MXN256.55.

When is next earnings date of Smith & Nephew PLC(MEX:SN1 N)?

The next earnings date of Smith & Nephew PLC(MEX:SN1 N) is 2026-08-26.

Does Smith & Nephew PLC(MEX:SN1 N) pay dividends? If so, how much?

Smith & Nephew PLC(MEX:SN1 N) does not pay dividend.

Press Release

	Subject	Date
	Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich	2023-10-11
	Smith+Nephew announces 510(k) clearance of its AETOS™ Shoulder System for anatomic and reverse shoulder replacement	2023-06-12
	Smith+Nephew helps personalize robotically-enabled surgery with AI-powered planning software and data visualization platform	2023-05-16
	Smith+Nephew receives Innovative Technology contract from Vizient for PICO™ Single Use Negative Pressure Wound Therapy Systems	2023-05-02
	New evidence demonstrates Smith+Nephew's COBLATION™ Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques	2023-03-23
	Smith+Nephew receives Innovative Technology designation from Vizient for LEAF™ Patient Monitoring System	2023-01-30
	Smith+Nephew expands procedural innovation with introduction of JOURNEY™ II ROX™ Total Knee Solution	2022-11-01
	Smith+Nephew's OXINIUM™ Technology Tour of Change touches down at the Pro Football Hall of Fame during enshrinement weekend	2022-08-04
	SMITH+NEPHEW SHARES NEW RESEARCH THAT ESTIMATES 3.5 BILLION HOURS OF NURSE TIME COULD BE RELEASED BY 2030 THROUGH SHARED WOUND CARE AND USE OF LONG-WEAR ADVANCED FOAM DRESSINGS	2022-07-14
	Smith+Nephew announces first robotic-assisted surgery using its LEGION™ CONCELOC™ Cementless Total Knee System	2022-07-10

10/Page

Articles on Smith & Nephew PLC

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.